What drug class is paromomycin?

paromomycin is classified as a Antiprotozoal.

Is there a generic version of paromomycin?

Yes, generic versions of paromomycin are available. See the Exact Equivalents section above for FDA-rated generic alternatives.

How does paromomycin work?

paromomycin mechanism of action information is available in the Drug Information section of this page.

Paromomycin

Also sold as: Humatin

AntiprotozoalPrescription OnlyGeneric Available

Related Medications

Important: Only drugs listed as "Exact Equivalents" (FDA AB-rated) are confirmed interchangeable. All other listings are for informational reference only and do NOT indicate that drugs can be substituted without a physician's explicit guidance.

Same Pharmacologic Class

These drugs share a pharmacologic classification but are NOT interchangeable. Listing here does not imply clinical equivalence. A physician must evaluate each drug individually for the patient's specific condition.

Classification: Antiprotozoal (source: RxClass/NLM)

Insurance Coverage User-Reported

Community Data Disclaimer: Insurance coverage information below was submitted by RxSaurus users and has not been verified by RxSaurus. Coverage varies by plan, year, geography, and individual circumstances. Drug formulary status, prior authorization requirements, and tier placements change frequently. Always verify coverage directly with the patient's insurance plan or pharmacy benefits manager before prescribing or dispensing.

No community coverage data yet for paromomycin.

Coverage data submission coming soon.

Drug Information

Indications & Uses

INDICATIONS AND USAGE Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Dosage & Administration

DOSAGE AND ADMINISTRATION Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days. Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

Side Effects (Adverse Reactions)

ADVERSE REACTIONS Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily. To report SUSPECTED ADVERSE REACTIONS, Waylis Therapeutics LLC at 844-200-7910 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contraindications

CONTRAINDICATIONS Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.

Verify with Primary Sources

Always verify clinical information with authoritative sources.

DailyMed (NLM/NIH)FDA-approved drug labeling↗FDA Orange BookTherapeutic equivalence data↗RxNorm (NLM/NIH)Drug nomenclature & relationships↗